real world evidence · 4 cdrh rwe guidance • describes the potential use of real world evidence...
TRANSCRIPT
![Page 1: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/1.jpg)
Real World Evidence
David B. Martin, MD, MPHCaptain, US Public Health Service
Office of Medical PolicyCDER | US FDA
![Page 2: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/2.jpg)
2
Learning Objectives
• Become familiar with the legislative background for the FDA’s RWE program as well as FDA’s definitions for RWD and RWE
• Review FDA’s Framework for evaluating RWE
![Page 3: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/3.jpg)
3
21st Century Cures Act• FDA shall establish a program to evaluate the potential use of real world
evidence (RWE) to support:
– Approval of new indication for an drug approved under section 505(c)
– Satisfy post-approval study requirements
• Program is based on a framework that was issued in December 2018
– Describes the priority areas, remaining challenges and potential pilot opportunities that the program will address
• Draft Guidance to be issued by 2021
www.fda.gov
![Page 4: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/4.jpg)
4
CDRH RWE Guidance• Describes the potential use of Real World
Evidence throughout the total product lifecycle for devices
• Draft issued prior to 21st Century Cures Act
• Definitions of Real World Data and Real World Evidence are harmonized with the FDA Framework
• CDRH, CBER, and CDER are coordinating as the 21st CC RWE program proceeds
www.fda.govhttps://www.fda.gov/ScienceResearch/SpecialTopics/RealWorldEvidence/default.htm
![Page 5: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/5.jpg)
5
Definitions
• Real-World Data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.
• Real-World Evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.
www.fda.gov
![Page 6: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/6.jpg)
6
Potential Benefits of RWE• Improve the efficiency of clinical research by capitalizing on data that
is being captured every day
– Digitization of health care as well as new analytics provide new opportunities to close the divide between research and clinical care
• Additional settings, access to more diverse populations
• Big data – potential for detection of infrequent events or enrollment from relatively rare source populations
• Lower resource intensity – more questions answered
www.fda.gov
![Page 7: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/7.jpg)
7
Benchmark• Goal is to distinguish the effect of the drug from other influences such
as spontaneous change in disease course, placebo effect, or bias
• Common practices:
• Probabilistic control of confounding through randomization
• Blinding
• Controlled/standardized outcome assessment; Adjudication criteria; Audits
www.fda.gov
![Page 8: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/8.jpg)
8
Framework for Evaluating RWE• Whether the RWD are fit for use
• Whether the trial or study design used to generate RWE can provide adequate scientific evidence to answer or help answer the regulatory question
• Whether the study conduct meets FDA regulatory requirements
www.fda.gov
![Page 9: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/9.jpg)
9
RWD Fitness for Use
www.fda.gov
![Page 10: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/10.jpg)
10
The Current State• Data in pathology, radiology and lab reports as well as
clinical notes are often unstructured (~80%)
• Linkage may be necessary to capture care in multiple health systems
• Structured data ≠ Standardized data
• Clinical outcome measures for drug approvals may not be used or consistently recorded in practice
www.fda.gov
![Page 11: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/11.jpg)
11
Oncology Example
• mCODE: Minimal Clinical Oncology Data Elements - Data Model developed by ASCO, Alliance, and MITRE
www.fda.gov
![Page 12: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/12.jpg)
12
FDA MyStudies• Mobile App
– Standard frameworks - ResearchKit (iOS), ResearchStack (Android)
• Web-based Configuration Portal (WCP)– Enables support of multiple types of medical product effectiveness and
safety studies with minimal software development
• Secure Storage Environment– Generates secure tokens
– Separates registration information and responses
– Partitioned for multisite, decentralized, or distributed models
www.fda.gov
https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm625228.htmhttps://www.fda.gov/Drugs/ScienceResearch/ucm624785.htmhttps://github.com/PopMedNet-Team/FDA-My-Studies-Mobile-Application-System
![Page 13: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/13.jpg)
13
Mobile + Wearables Example
• Presented by Ernesto Ramirez, Ph.D., Evidation, at the Duke-Margolis Developing RWD and Evidence Meeting, October 3, 2019
www.fda.gov
![Page 14: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/14.jpg)
14
RWE Study Design
www.fda.gov
![Page 15: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/15.jpg)
15
RWE incorporating Randomization• Some factors to consider
– What types of interventions might be well-suited to routine clinical care settings?
– Capture of Existing Endpoints vs. Novel Endpoints
– RWD lags, if applicable
– Masking/Blinding
– Monitoring
– Source data
www.fda.gov
![Page 16: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/16.jpg)
16
RELIANCE trial• RofLumilast or Azithromycin to prevent COPD Exacerbations
– Randomized “real world” trial; 1,600 adults in each arm
– Azithromycin - macrolide with anti-inflammatory properties
– Roflumilast - noncorticosteroid anti-inflammatory; phosphodiesterase type 4 inhibitor
– Both guideline recommended but Roflumilast is FDA approved for this indication
• Primary outcomes
– All cause hospitalization
– All cause mortality
• Follow-up
– 6-36 months, no visits, call center, Patient Portal, Site EMR
– CMS linkage through FDA-Catalyst for outcomes and exposures
www.fda.gov
![Page 17: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/17.jpg)
17
RCT Duplication Demonstration Projects
• Substantial assessment of the comparability of randomized and non-randomized designs necessary to gain confidence that non-interventional designs could provide credible evidence of drug effect
– Comparable results with similar clinical questions?
– Reasons for differences?
• Retrospective replication: 40 trials -> approximately 30
• Prospective replication: 10 trials -> approximately 7 in advance of trial findings
www.fda.gov
![Page 18: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/18.jpg)
18
Regulatory Considerations
www.fda.gov
![Page 19: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/19.jpg)
19
Regulatory Considerations
• Develop guidance as needed regarding the applicability of regulatory requirements to use of RWD in RCTs and observational studies, including informed consent, oversight, transparency
www.fda.gov
![Page 20: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/20.jpg)
20
Data Standards
www.fda.gov
![Page 21: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/21.jpg)
21
Data Standards in the Drug Lifecycle
www.fda.gov
![Page 22: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/22.jpg)
22
Data Standards and Implementation
www.fda.gov
RWD Submission Standards
Assess data standards and
implementation strategies in the drug
lifecycle
Identify gaps between RWD/ RWE data standards and
existing systemsCollaborate with Stakeholders to
adopt or develop standards and
implementations strategies
![Page 24: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/24.jpg)
24
Challenge Questions
• True/False. Real-world data sources include only electronic health records (EHRs) and medical claims and billing data.
![Page 25: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/25.jpg)
25
Challenge Questions
• True/False. Real-world data sources include only electronic health records (EHRs) and medical claims and billing data.
![Page 26: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/26.jpg)
26
Challenge QuestionsWhich topics are within the scope of the FDA RWE Program?
• A. Fitness for Use (EHR, claims, registries, digital health technologies)
• B. Regulatory Considerations
• C. Study Design (clinical trials in the real world setting, observational studies)
• D. Data Standards
• E. All of the Above
![Page 27: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/27.jpg)
27
Challenge QuestionsWhich topics are within the scope of the FDA RWE Program?
• A. Fitness for Use (EHR, claims, registries, digital health technologies)
• B. Regulatory Considerations
• C. Study Design (clinical trials in the real world setting, observational studies)
• D. Data Standards
• E. All of the Above
![Page 28: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/28.jpg)
![Page 29: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/29.jpg)
29
About These Remaining Slides…
• To make sure you do not lose any of the Layout Options for your slides, you should not delete the reaming slides
• You can delete them if you are sure you will never want to add or change slides with different layouts
![Page 30: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/30.jpg)
30www.fda.gov
![Page 31: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/31.jpg)
31www.fda.gov
![Page 32: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/32.jpg)
32www.fda.gov
![Page 33: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/33.jpg)
33www.fda.gov
![Page 34: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/34.jpg)
34www.fda.gov
![Page 35: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/35.jpg)
35w
ww
.fda.gov
![Page 36: Real World Evidence · 4 CDRH RWE Guidance • Describes the potential use of Real World Evidence throughout the total product lifecycle for devices • Draft issued prior to 21st](https://reader036.vdocuments.us/reader036/viewer/2022071220/605aed289e280526e2292653/html5/thumbnails/36.jpg)
36www.fda.gov